• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email
    For Immediate Release:
    May 19, 2023

    Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. 

    “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a rare and serious genetic skin disorder,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s action demonstrates the FDA’s ongoing commitment to supporting the development and evaluation of new treatments that address unmet needs for rare diseases or conditions.”

    DEB is a genetic disorder that affects the connective tissue in the skin and nails and results from mutation(s) in the COL7A1 gene. This gene encodes type VII collagen (COL7), which is an essential protein that helps strengthen and stabilize the outer and middle layers of the skin. When COL7A1 is deficient, skin layers can separate, causing painful and debilitating blisters and wounds. DEB usually presents itself at birth and is divided into two major types depending on the inheritance pattern: recessive dystrophic epidermolysis bullosa (RDEB) and dominant dystrophic epidermolysis bullosa (DDEB).

    Symptoms can vary widely among affected people. Individuals with DDEB typically have mild cases with blistering primarily affecting the hands, feet, knees, and elbows. RDEB cases can be painful and debilitating, often involving widespread blistering that can lead to vision loss, disfigurement, and other serious medical complications, which could be fatal.

    Vyjuvek is a genetically modified (engineered in a laboratory) herpes-simplex virus used to deliver normal copies of the COL7A1 gene to the wounds. COL7 molecules arrange themselves into long, thin bundles that form anchoring fibrils that hold the epidermis (skin) and dermis together, which is essential for maintaining the integrity of the skin. Vyjuvek has also been modified to eliminate its ability to replicate in normal cells. Vyjuvek is mixed into an excipient (non-active ingredient) gel prior to topical application. A healthcare professional evenly applies Vyjuvek gel in droplets to a patient’s wounds once a week.  

    The safety and effectiveness of Vyjuvek was established primarily in a randomized, double-blinded, placebo-controlled study involving a total of 31 subjects with DEB, including 30 subjects with RDEB and one subject with DDEB. In the study, two DEB wounds of comparable size on each patient were identified and randomized to receive either topical administration of Vyjuvek or the placebo on a weekly basis. The age of the subjects ranged from 1 year to 44 years (mean age 17 years). Efficacy was established by improved wound healing, defined as the difference in the proportion of confirmed complete (100%) wound closure between the Vyjuvek-treated and the placebo-treated wounds at 24 weeks. Sixty-five percent of the Vyjuvek-treated wounds completely closed while only 26% of the placebo-treated wound completely closed. 

    In addition, in a different clinical study, two young patients with RDEB (6 and 7 months of age, respectively) received topical Vyjuvek weekly without any new safety findings. 

    The most common adverse reactions associated with Vyjuvek included itching, chills, redness, rash, cough and runny nose.

    Patients or caregivers should take the following precautions during treatment with Vyjuvek:

    • Avoid direct contact with treated wounds (e.g., touching and scratching) and dressings of treated wounds for approximately 24 hours following Vyjuvek application. In the event of accidental exposure, patients and exposed individuals should clean the affected area.
    • Wash hands and wear protective gloves when changing wound dressings.
    • Disinfect bandages from the first dressing change following Vyjuvek treatment with a virucidal agent, such as 70% isopropyl alcohol, 6% hydrogen peroxide, or <0.4% ammonium chloride, and dispose of the disinfected bandages in a separate sealed plastic bag in household waste. Dispose of the subsequent used dressings and cleaning materials into a sealed plastic bag and dispose in household waste.

    This application received Orphan Drug and Fast Track designations. Vyjuvek also received Regenerative Medicine Advanced Therapy and Priority Review designations and a Rare Pediatric Disease Priority Review Voucher. The FDA’s rare pediatric disease priority review voucher program is intended to encourage development of new drugs and biologics to prevent and/or treat rare diseases in children. 

    The approval of Vyjuvek was granted to Krystal Biotech, Inc.

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    Carly Kempler
    240-672-8872
    Consumer:
    888-INFO-FDA

    Get the next $KRYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    4/18/2023$102.00Buy
    Stifel
    2/28/2023$79.00 → $124.00Neutral → Buy
    Goldman
    More analyst ratings

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

      PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 14, 2025 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology co

      5/7/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

      VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. "We were thrilled to receive VYJUVEK approval in Europe, and with the p

      5/6/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

      VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that on April 23, 2025, the European Commission (EC) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) who have mutations in the collagen type VII alpha 1 chain (COL7A1) gene, starting from birth. VYJUVEK is designed to address the geneti

      4/28/25 7:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, R&D Krishnan Suma sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,463,711 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:06:28 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Krishnan Krish S sold $8,889,525 worth of shares (50,000 units at $177.79), decreasing direct ownership by 2% to 1,533,056 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      3/13/25 6:04:23 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Romano Kathryn covered exercise/tax liability with 8,054 shares, sold $131,415 worth of shares (750 units at $175.22) and converted options into 12,500 shares, increasing direct ownership by 24% to 19,318 units (SEC Form 4)

      4 - Krystal Biotech, Inc. (0001711279) (Issuer)

      2/28/25 7:01:45 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Leadership Updates

    Live Leadership Updates

    See more
    • Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

      PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

      4/7/25 4:30:00 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

      PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my

      1/14/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

      6/7/24 6:09:00 PM ET
      $ADTN
      $ALTR
      $ATNI
      $BMRN
      Telecommunications Equipment
      Utilities
      Computer Software: Prepackaged Software
      Technology

    $KRYS
    Financials

    Live finance-specific insights

    See more
    • Krystal Biotech Announces First Quarter 2025 Financial and Operating Results

      VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical readouts in 2025 - CF, AATD, ocular complications of DEB, and aesthetics Strong balance sheet, ending the quarter with $765.3 million in cash and investments PITTSBURGH, May 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2025 and provided a business update. "We were thrilled to receive VYJUVEK approval in Europe, and with the p

      5/6/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025

      PITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results on Tuesday, May 6, 2025, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Tuesday, May 6, 2025, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster4.com/Webcast/Page/3018/52291. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of th

      4/17/25 8:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

      Fourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong balance sheet, ending the quarter with $749.6 million in cash and investments PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today reported financial results for the fourth quarter and full year ending December 31, 2024 and provided a business update. "Last year, our commercial and financial strength allowed us to deliver significant earnings growth, continue to build out a glob

      2/19/25 7:00:00 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    SEC Filings

    See more
    • Krystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:09:31 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Krystal Biotech Inc.

      10-Q - Krystal Biotech, Inc. (0001711279) (Filer)

      5/6/25 8:08:58 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Krystal Biotech, Inc. (0001711279) (Filer)

      4/28/25 8:53:15 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

      For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

      5/19/23 1:48:20 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

      SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

      11/14/24 9:00:58 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

      SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

      11/12/24 10:32:12 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Krystal Biotech Inc.

      SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

      10/16/24 12:28:49 PM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Krystal Biotech with a new price target

      Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

      3/5/25 7:35:58 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Krystal Biotech downgraded by Citigroup with a new price target

      Citigroup downgraded Krystal Biotech from Buy to Neutral and set a new price target of $204.00 from $195.00 previously

      8/6/24 8:53:09 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Krystal Biotech with a new price target

      Goldman initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $160.00

      11/20/23 7:47:05 AM ET
      $KRYS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care